Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, February 2006, p. 281-288, Vol. 13, No. 2
1071-412X/06/$08.00+0 doi:10.1128/CVI.13.2.281-288.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Division of Pediatric Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205,1 Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205,2 Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 212873
Received 9 June 2005/ Returned for modification 8 September 2005/ Accepted 13 December 2005
|
|
|---|
B and serum levels of tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-10. Disparate classes of anesthetic agents produce the same effects on the inflammatory response, which is also independent of the inbred mouse strain used. These results suggest that anesthesia has an important impact on the outcome from endotoxemia. Moreover, the immunomodulatory effects of anesthetics should be considered when interpreting data from experimental animal models. |
|
|---|
The alteration in the balance between pro- and anti-inflammatory agents is likely responsible for the development of septic shock. The incidence of sepsis in the United States is approximately 750,000 per year, with mortality of 30 to 50% (29). Sepsis is usually initiated by microbial agents or their products, such as lipopolysaccharide (LPS), an outer membrane component of gram-negative bacteria. LPS induces a rapid release of inflammatory mediators, such as tumor necrosis factor alpha (TNF-
), gamma interferon, interleukin-1ß (IL-lß), and IL-6. The secretion of these proinflammatory mediators is followed by release of counterregulatory cytokines, such as IL-10 and transforming growth factor ß (8, 21). In the present study, we show that anesthetics modify the inflammatory response induced by LPS and affect the outcome from endotoxic shock.
|
|
|---|
, IL-6, and IL-10 plasma levels were determined by an enzyme-linked immunosorbent assay (Biosource, Camarillo, CA). For survival studies, animals were given ad libitum access to standard chow and water postprocedurally. Other anesthetic agents. Mice were injected with LPS intraperitoneally and simultaneously anesthetized for 1.5 h with pentobarbital (70 mg/kg i.p., Nembutal; Abbott Laboratories, Chicago, IL); ketamine (150 mg/kg i.p., Ketaject; Phoenix Pharmaceutical Inc., St. Joseph, MO) plus xylazine (15 mg/kg i.p., Xylaject; Phoenix Pharmaceutical Inc.); medetomidine (1 mg/kg i.p., Domitor; Orion Corp., Finland) plus ketamine (75 mg/kg i.p.); halothane (2% inhaled; Halocarbon Laboratories, River Edge, NJ); or ether (inhaled from gauze-soaked nose cone; J.T. Baker, Phillipsburg, NJ). Blood samples were collected via cardiac puncture immediately following the anesthetic period. Plasma was isolated via centrifugation and stored at 80°C.
Atropine treatment. B6 mice were injected with atropine (Sigma-Aldrich, St. Louis, MO) prepared in sterile saline. The atropine was injected intraperitoneally at a dose of 1 mg/kg 10 min before the administration of LPS or the simultaneous administration of LPS and anesthesia (for 1 h). Two controls were used: mice injected with saline only (rather than atropine) 10 min prior to LPS, and mice injected with atropine without any further intervention (no LPS). Control animals received a comparable volume of saline.
Electrophoretic mobility shift assay.
Nuclear extracts were isolated using a modification of the protocol described by Dignam et al. (19). Briefly, 100 mg of liver was resuspended in 1 ml of hypotonic buffer (HEPES, 10 mM [pH 7.9]; KCl, 10 mM; EDTA, 0.1 mM; EGTA, 0.1 mM; dithiothreitol, 1 mM; phenylmethylsulfonyl fluoride, 0.5 mM; and 10 µg/ml each of leupeptin, aprotinin, and pepstatin), homogenized, and incubated on ice for 10 min. Samples were centrifuged at 850 x g at 4°C for 10 min, and the pellet was resuspended in 1 ml of buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride) and incubated on ice for 10 min. Nonidet P-40 at a final concentration of 0.6% was added, and lysates were vortexed for 1 min. Nuclei were isolated by centrifugation at 2,800 x g for 10 min at 4°C, and the pellet was resuspended in 200 µl of buffer C (HEPES, 20 mM [pH 7.9]; 1 M NaCl; 5% glycerol; 1 mM EDTA; 1 mM EGTA; 1 mM dithiothreitol; 0.5 mM phenylmethylsulfonyl fluoride; and 10 µg/ml each of leupeptin, aprotinin, and pepstatin) and gently agitated on an orbital shaker at 4°C for 30 min. The suspension was centrifuged at 14,000 x g for 10 min at 4°C, and the supernatant was aliquoted and stored at 80°C. An NF-
B DNA binding assay was performed using a double-stranded oligonucleotide containing the consensus binding site for NF-
B (Promega, Madison, WI), and the fragment was end labeled with [
-32P]ATP (7,000 Ci/mmol; NEN Life Science Products, Boston, MA) by using T4 polynucleotide kinase (Promega, Madison, WI) as described previously (23).
Endotoxin detection. B6 mice (n = 3) were injected with LPS and simultaneously anesthetized with isoflurane or allowed to remain nonanesthetized (LPS control). Blood samples were obtained via cardiac puncture 0, 5, 10, 20, and 30 min after LPS injection, and samples were stored in sterile, pyrogen-free K+EDTA tubes. Plasma was isolated via centrifugation and stored at 80°C. Endotoxin levels were measured in plasma by use of an automated turbidimetric Limulus amebocyte lysate assay (BioWhittaker, Walkersville, MD). Before testing, serum was diluted 1:15 with endotoxin-free water and heated at 70°C for 7 min to remove inhibitors in plasma.
Statistical analysis. Survival was analyzed via Kaplan-Meier analysis using the log rank test. Cytokine data shown are means ± standard errors of the means (SEM). General differences in cytokine levels among all groups were determined using one-way analysis of variance, with multiple pairwise comparisons by the Student-Newman-Keuls method being used to elucidate specific significances in these parameters between groups. All tests were two-tailed, and differences were considered significant when P was <0.05. Analysis was performed using Microsoft Excel (Microsoft Corporation, Seattle, WA) and SigmaStat (SPSS Incorporated, Chicago, IL) software.
|
|
|---|
![]() View larger version (16K): [in a new window] |
FIG. 1. Isoflurane ameliorates the response to endotoxic shock. (A) B6 mice (n = 13) were injected with LPS (20 mg/kg) and then (i) were anesthetized for 1 h (simultaneous) or (ii) received no further treatment (LPS control). Mortality was monitored for 72 h following LPS injection. Increased survival was observed among the simultaneous animals (85%) compared to control animals (23%) (P < 0.01). (B) Levels of TNF- , IL-6, and IL-10 in mice (n = 10) were measured 1.5 h after LPS (15 mg/kg) injection. Lower cytokine levels were observed with the simultaneous group than with the post-LPS injection and control groups (P < 0.05 for all). (C) Mice (n = 8) were anesthetized for 1 h and were injected with LPS (15 mg/kg) immediately (pretreatment group) or after a 30-min recovery (pretreatment/recovery group). Attenuation of cytokine levels was most marked in the simultaneous group. Data are presented as means ± SEM. *, P < 0.05 versus LPS control; , P < 0.05 versus post-LPS injection; , P < 0.05 versus pretreatment/recovery; , P < 0.05 versus pretreatment.
|
plasma levels was observed for the simultaneous group in comparison with levels for the other two groups (Fig. 1B). IL-6 and IL-10 levels were also reduced in the simultaneous and post-LPS injection groups compared to levels for the control group (Fig. 1B). To further characterize these findings, the effect of isoflurane pretreatment was investigated. Compared to levels in the LPS control group, TNF-
plasma levels 1.5 h after LPS injection were reduced in both the pretreatment/recovery and the pretreatment group. However, TNF-
levels for the two pretreatment groups were still significantly greater than the level for the simultaneous group (Fig. 1C). In contrast, IL-6 plasma levels were reduced only with the pretreatment and simultaneous groups, compared to levels for the control and pretreatment/recovery groups (Fig. 1C). Finally, IL-10 plasma levels in both pretreatment groups were greater than levels in the simultaneous and control groups (Fig. 1C). These data suggest that the suppressive effect of isoflurane on LPS-induced cytokine production increases survival in anesthetized animals. We also evaluated the effect of isoflurane anesthesia duration on the inflammatory response induced by LPS. Mice were injected with LPS and then administered continuous anesthesia for 0, 10, 30, or 60 min. Cytokine plasma levels were measured 1.5 h after injection. Decreasing levels of TNF-
and IL-6 were observed with increasing duration of anesthesia, whereas IL-10 levels decreased only with the 60-min anesthesia group (Fig. 2). Therefore, the timing and duration of isoflurane administration are important in modulating the LPS-induced inflammatory response.
![]() View larger version (10K): [in a new window] |
FIG. 2. Decreasing LPS-induced cytokine production correlates with increasing duration of anesthesia. B6 mice (n = 10) were injected with LPS (15 mg/kg) and anesthetized for 0, 10, 30, or 60 min. Serum levels of TNF- , IL-6, and IL-10 were measured 1.5 h after LPS injection. Reductions in TNF- and IL-6 plasma levels were inversely proportional to the anesthetic duration. IL-10 levels were depressed only after 60 min of anesthesia. Data are presented as means ± SEM. *, P < 0.05 versus 0 min; , P < 0.05 versus 10 min; , P < 0.05 versus 30 min.
|
, IL-6, and IL-10 compared to levels for the LPS control group (Table 1). Halothane, ether, and ketamine-medetomidine were also found to attenuate cytokine production (data not shown). These results suggest that there is a common pathway of anesthetic attenuation of the inflammatory response. |
View this table: [in a new window] |
TABLE 1. Effects of different anesthetics on plasma cytokine levelsa
|
, IL-6, and IL-10 compared to use of LPS alone (Table 2), indicating that the effect of isoflurane is broad with respect to host genetic background. |
View this table: [in a new window] |
TABLE 2. Effect of isoflurane on different inbred mouse strains
|
levels (P < 0.01) and increased IL-10 levels (P < 0.001), with no change in IL-6 levels (Fig. 3). Most notably, isoflurane still significantly attenuated serum production of all three plasma cytokines (to levels comparable to atropine without LPS) in atropine-treated animals (10 min pre-LPS). These observations suggest that the effect of isoflurane on the inflammatory process may be independent of the cholinergic pathway and, thus, is unlikely to be mediated by the vagus nerve or nicotinic receptors.
![]() View larger version (8K): [in a new window] |
FIG. 3. Mechanism of anesthesia immunomodulation does not involve the cholinergic pathway. B6 mice (n = 7) were injected i.p. with atropine (1 mg/kg) (columns II, III, and IV) or saline (equivalent volume) (column I) 10 min before LPS injection (15 mg/kg). The group depicted by column III received isoflurane anesthesia for 60 min. Cytokine plasma levels were measured 1.5 h after LPS injection. LPS-induced TNF- plasma levels decreased while IL-10 levels increased after administration of atropine. With chemically vagotomized mice (atropine), anesthesia still decreased TNF- , IL-6, and IL-10, all to levels similar to that with atropine alone (no LPS). Data are presented as means ± SEM. *, P < 0.05 versus column I; , P < 0.05 versus column II.
|
B, cytokine production, and levels of LPS in circulation.
We also investigated the activation of NF-
B, a central component of the LPS response. B6 mice were injected with LPS alone or with LPS plus simultaneous isoflurane anesthesia for 0, 5, 10, 20, 30, or 60 min. Liver samples were harvested at the end of the anesthetic period, and NF-
B binding to DNA was determined by a gel shift assay. NF-
B normally resides in the cytoplasm bound to the inhibitor I
B complex. After stimulation with LPS, I
B is phosphorylated and degraded, allowing NF-
B to translocate into the nucleus, resulting in the transcription of many inflammatory genes (4, 16). NF-
B DNA binding was retarded in samples from isoflurane-anesthetized mice in comparison with samples from the nonanesthetized group (Fig. 4A). Thus, anesthesia appears to cause a delay in the activation of NF-
B.
![]() ![]() View larger version (84K): [in a new window] |
FIG. 4. Anesthetized mice injected with LPS show delayed NF- B nuclear activity and a shift in cytokine kinetics. B6 mice (n = 3) were injected with LPS alone or with simultaneous anesthetization with isoflurane for 0, 5, 10, 20, 30, or 60 min. Liver samples were harvested at the end of the anesthetic period and nuclei were isolated. (A) NF- B binding to DNA was monitored by a gel shift assay. A delay in the activation of NF- B or translocation of NF- B into the nucleus was observed for mice exposed to isoflurane in comparison with results for nonanesthetized mice. P, probe alone. (B) This delay correlated with a 1- to 2-h shift in cytokine kinetics for anesthetized mice (n = 7) compared to LPS control mice. Data are presented as means ± SEM. *, P < 0.05 versus LPS control.
|
after LPS injection also shifted to a later time point in anesthetized mice than in nonanesthetized controls (Fig. 4B). IL-6 levels were elevated overall and peaked earlier in the nonanesthetized group than in mice treated with isoflurane (Fig. 4B). Finally, IL-10 levels rose later and peaked higher in the isoflurane-treated group than in the nonanesthetized controls (Fig. 4B). The concentrations of LPS in systemic circulation following its intraperitoneal injection in both anesthetized and nonanesthetized mice were compared. The appearance of LPS in circulation was slower in anesthetized mice than in the control group (Fig. 5), which correlates with the delayed activation of NF-
B and cytokine kinetics.
![]() View larger version (16K): [in a new window] |
FIG. 5. Isoflurane treatment reduces systemic LPS circulation. B6 mice (n = 3) were injected with LPS and simultaneously anesthetized with isoflurane or allowed to remain nonanesthetized (LPS control). Blood samples were obtained via cardiac puncture 0, 5, 10, 20, and 30 min after LPS injection. Endotoxin levels were measured in plasma by use of a turbidimetric Limulus amebocyte lysate assay (BioWhittaker, Walkersville, MD). Data are presented as means ± SEM. *, P < 0.05 versus LPS control. EU, endotoxin units.
|
|
|
|---|
The multiple detrimental effects of severe sepsis are attributed to an overwhelming inflammatory response. We found that administration of anesthetics simultaneously with LPS injection delayed the peak of TNF-
from 1.5 to 2 h (Fig. 4B) without affecting the peak level. Similarly, the time of maximum IL-6 expression changed from 2 to 4 h in the control group versus the anesthetized group. This delay in cytokine profile correlated with delayed NF-
B DNA binding activity. We also found a decrease in cytokine production proportional to an increase in the duration of anesthesia. The anti-inflammatory cytokine IL-10 displayed higher levels in anesthetized mice than in nonanesthetized mice. Prior studies have shown that IL-10 decreases TNF-
levels and increases survival in the cecal ligation and puncture and LPS models of sepsis (31, 38). It is possible that elevation of IL-10 may be at least in part responsible for the decrease in mortality in mice treated with isoflurane. Our findings regarding changes in cytokine kinetics after LPS injection are consistent with prior studies using the anesthetic ketamine, which decreased systolic arterial pressure, acid-base changes, and cytokine production when administered immediately before LPS injection (43). Isoflurane pretreatment has also been shown to prevent endothelial and vascular smooth muscle cell injury in vitro (15) and in vivo (36). Ketamine-xylazine has been shown to attenuate gastrointestinal inducible nitric oxide synthase (iNOS) expression (28) and activity in activated alveolar macrophages exposed to LPS (32). Furthermore, volatile anesthetics have been implicated in the reduction of mRNA and protein levels of iNOS and NOS activity after LPS or gamma interferon stimulation (47). The anesthetic protection that we observed could be due to attenuation of iNOS expression, thereby preventing the cardiovascular collapse during sepsis partially caused by upregulation of iNOS and cytokine release (20). Another potential mechanism by which anesthetics may exert their protection against endotoxic shock is by blocking major signal pathways for cytokine production. We found that isoflurane delayed the activation of NF-
B, a central component of the LPS response (4), which is consistent with previous reports (40).
LPS enters circulation slowly in anesthetized mice in comparison with nonanesthetized animals. This delayed appearance of LPS in circulation may be explained by alterations of hemodynamics. Indeed, prior studies have shown that anesthetized mice have reduced heart rate, mean arterial pressure, and plasma volume compared to conscious mice (5). A slower delivery of LPS to target tissues in the anesthetized mice may allow cells to clear the endotoxin more efficiently, avoiding secondary toxic effects. We speculate that anesthesia protects against endotoxic shock through a mechanism similar to ischemia preconditioning. In fact, several reports have indicated that anesthetics offer cardioprotection (44) and neuroprotection (25, 48) to subsequent ischemic events through a concept known as "anesthesia preconditioning" (15). The mechanism of this protective role of anesthetics has been attributed to adenosine A1 receptor activation and the opening of mitochondrial ATP-regulated potassium channels (39, 44). These channels may have an antiapoptotic effect by inhibiting cytochrome c release and preventing the loss of mitochondrial membrane potential (2). Other studies suggest that volatile anesthetics prime mitochondrial KATP channels through protein kinase C-coupled signaling pathways (49) or through the release of reactive oxygen species (3, 35, 41). The concept of anesthesia preconditioning has been extended to endothelial and vascular smooth muscle cells (10, 15, 36). Furthermore, anesthetics have been shown to prevent lymphocyte and neuronal apoptosis and increase survival during ischemia/reperfusion and under septic conditions (13, 22, 30).
The observed effect of anesthesia on the LPS response could also be related to a direct effect on the nervous system. A correlation between the inflammatory response and the nervous system was recently reported and coined the "cholinergic anti-inflammatory pathway" (45). Stimulation of the peripheral vagus nerve releases acetylcholine, which has been shown to block TNF-
release in LPS-stimulated animals (9). In contrast, others have shown that subdiaphragmatic vagotomy blocks LPS toxicity (34). Chemical vagotomy using atropine, a muscarine receptor antagonist, has been shown to attenuate the decrease of TNF-
production in LPS-challenged animals (6). One hypothesis is that isoflurane stimulates the release of acetylcholine, resulting in protection from endotoxic shock; thus, the protective effect of isoflurane should be blocked by administration of atropine. We found that the decrease in cytokine production after isoflurane anesthesia was not modified by administration of atropine. This observation suggests that the cholinergic anti-inflammatory pathway is not responsible for the effect of isoflurane on the inflammatory process.
Overall, our observations suggest that general anesthesia may be of vital importance in the treatment of critically ill patients. Finally, because anesthetics are an intrinsic component of any experimental animal model of injury or inflammation, special consideration should be made for the use of anesthetics in the design and interpretation of results from such experiments.
We thank Rebecca Torres for her editorial assistance.
|
|
|---|
B signaling pathways. Ann. N. Y. Acad. Sci. 1030:1-13.[CrossRef][Medline]
or IL-1ß on cellular signaling and mediator production. J. Leukoc. Biol. 70:821-829.
B activation and cytokines production in the intestine. Acta Anaesthesiol. Scand. 48:317-321.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»